Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We think has a differentiated safety efficacy profile |
| As you point out, we've also had market share gains in a number of other geographies |
| We grew and advanced our late stage pipeline and we again delivered a strong financial performance highlighted by €3.8 billion of total recognized revenues, €1.2 billion of profit before tax, resulting in earnings per share on a fully diluted basis of €3.83 |
| This achievement not only showcased the versatility of our mRNA technology, but also highlighted our unique expertise and ability to execute fast |
| This is, we believe, favorable as COMIRNATY is a leading brand in the global COVID-19 vaccine market |
| We are truly excited by the potential our oncology pipeline holds to expand and improve on cancer treatment options for people around the world |
| Despite the decrease in our revenues in 2023, and despite the negative impact of these write-downs, we were able to both remain profitable in 2023 and grew our year-end financial position in respect of cash, cash equivalents and security investments to €17.7 billion compared to €13.9 billion at the end of 2022 |
| And we believe that we can position here the product with higher objective response rates plus higher durability of response |
| Lower spending in, for example, all our collaborations have been a main contributor as well as strong cost control measures |
| And this is offering now the opportunity to treat patients with advanced diseases, and not only with the ADCs, but bring in combinations and thereby ensure that even in patients with advanced disease, we really get a considerable clinical benefit |
| I'm particularly excited about our recent achievements in shaping our oncology pipeline |
| And to expand and strengthen our sustainable respiratory infectious disease vaccine business, building on the success of our COMIRNATY franchise |
| As we reflect on the achievements of 2023, we can proudly say that we have accelerated our IO and ADC programs, by not only starting new trials, but also successfully recruiting over 2,000 patients into our clinical trials across various indications |
| Having said that, the agreement has an important advantage |
| We believe this broad pipeline can deliver multiple new commercial product launches in the years ahead |
| We maintained a very high market share above 85% in Europe, and also grew our market share in countries like Japan, which have actually been pretty sizable from a volume perspective over the last 12 months |
| Our balance sheet has been further strengthened in 2023 and will continue to serve as a strategic asset to fuel long-term growth |
| Summarizing, we believe that our COVID-19 vaccine franchise and our innovative pipeline of product candidates will drive long-term value creation for the company |
| And thirdly, we believe to have a diversified clinical pipeline that offers multiple product growth opportunities for the years to come |
| But we're also seeing strong and encouraging data in other indications, such as refractory ovarian cancer and even seeing responses in lung cancer and other Claudin-6 positive tumors |
| Going into 2024, we do feel confident that we can continue to maintain a leadership position above the 50% mark globally |
| As you can see on this slide our COVID-19 vaccine business benefited from its lean fixed-cost structure in 2023 and generates very attractive positive results |
| What we have seen so far consistently, and in a number of cohorts is then the objective response rate which are very encouraging in various indications, and what we have also reported already first two -- first combination size and small-cell lung cancer and in triple-negative breast cancer, cancer patients, and what is really exciting in this indications is, it's not only the high response rate in the range of 60% to 75% in triple-negative breast cancer patients, but also the response rate in the patient population who are - are negative for immune infiltrate which is unusual, yes, for checkpoint blockade |
| Victoria Meissner With regard to your question to our BNT122 and its performance in PDAC, we are very encouraged, not surprised, but really encouraged, and this is also the reason why following the Data Disclosure of our Phase 1 PDAC trial, we have initiated a Phase 2 PDAC trial in the adjuvant setting with BNT122 which is enrolling of patients |
| So the collaboration contract gives us the optionality to actually scale into a multiproduct franchise in cell therapy, while keeping our fixed cost lean and allowing us to accelerate BNT211 forward |
| So we will see really tremendous transformation in the oncology, providing us the opportunity to open up indications where we believed in the past, patients |
| 2023 was another successful year for BioNTech on its journey to develop novel therapies for cancer and infectious diseases |
| On the next slide, I want to talk about our clinical achievements, in 2023, we successfully advanced our clinical pipeline and enhance our technology platforms, digital capabilities and infrastructure by executing across our key strategic initiatives |
| In 2023, we successfully executed strategic investments, acquisitions, licensing agreements and public private partnerships, enabling our continued progress towards building a multi-product, AI powered patient centric company |
| We find their Phase-1 data for our CD19/22 very encouraging, it's early, but it's encouraging and also the GD2 CAR we think is an interesting approach that could be complementary |
| Statement |
|---|
| Pfizer recognized additional write-downs of approximately €300 million that negatively impacted our top line figure compared to our initial expectations for Q4 |
| And as stated before, write-downs reported by our collaboration partner Pfizer, which negatively influenced our revenues |
| I think last year it is fair to say that part of the reduction in market share in the United States that we experienced was due to a lack or limited supply of pre-filled syringes |
| Following our gross profit share agreement for Pfizer, write-downs by our partner have a negative effect on BioNTech's revenue figure |
| This was primarily driven by lower COVID-19 vaccine market demand |
| The negative impact on our revenue for 2023 accumulated to a total of approximately €900 million |
| The drop was mainly caused by the decrease in COVID-19 vaccine sales |
| Write-downs related to EG inventory would typically have a negative impact on the gross profit in a P&L |
| It seems to imply a gross margin of 60% which is lower than previous levels of around 80% |
| As we have faced again additional write-downs above the previous announced ones that hit our revenue figure in Q4 2023 |
| market, but have seen some price pressure in the U.S |
| in Q4, some smaller inventory write down risks by our collaboration partner Pfizer |
| During the 2023 financial year, our R&D expenses were nearly €1.8 billion, slightly below our amended guidance from November of 2023 of €1.82 billion |
| As a consequence of the expected revenue range and taking into account cost of sales, R&D and all other expenses, we do not expect to be profitable in 2024 |
| Moving to SG&A expenses, during the 2023 financial year, we recognized €558 million in SG&A expenses slightly below the lower end of our amended guidance of €600 million to €650 million |
| That made our revenue guidance for 2023, challenging |
| While the sample size is still small and data cutoff is too early to draw conclusions on less frequent treatment, emergent adverse events and TEAEs with protracted manifestation, the safety profile was manageable and no new safety signals were observed |
| And Moderna has previously made a lot of noise about their pre-filled syringe |
| Please correct me if I'm wrong |
| Again, we were closely monitoring our spending to reflect the uncertainty on the revenues without jeopardizing the future needs in this area |
Please consider a small donation if you think this website provides you with relevant information